Research in Motion (RIM) has slashed prices for its PlayBook tablet amid speculation on the future of the company's corporate structure.
The company's US site on Tuesday announced a price cut that will run until 4 February. The special offer will reduce the cost of the 64GB PlayBook tablet from $699 to just $299.
The 16GB and 32GB models will also carry the $299 price tag, having previously been priced at $499 and $599 respectively.
The PlayBook was launched in June 2011, and is a major part of RIM's plan to overhaul and modernise its BlackBerry mobile platform. However, sales have fallen woefully short of the company's expectations.
RIM's smartphone operation has fared little better. Sluggish sales in the face of increased competition from the iOS, Android and Windows Phone platforms have pushed RIM's stock to historic lows and put shareholders on edge.
The Canadian company's poor performance could soon lead to a major shakeup for the company's board of directors. Canada's Financial Post yesterday cited sources within the company in reporting that co-chief executives Mike Lazaridis and Jim Balsillie will relinquish their roles as chairmen of RIM's board.
RIM's leadership has been called into question by investors and industry pundits, with some calling for the company to break up its mobile hardware and communications services into separate firms.
Rob Enderle, founder and principal analyst for the Enderle Group, suggested Lazaridis and Balsillie's days at the company may be numbered.
"The firm is in a spiral and will need to make some dramatic changes to pull out at this point," Enderle told V3.
"They seem to be setting up for just such an event but it is too early to tell how extensive it will be."
Ssupermassive black hole is so big it corresponds to four per cent of the galaxy's total mass
Imminent attack will target a single bank with cloned cards used to fraudulently withdraw millions over one weekend
Using photocatalysts to convert carbon dioxide into usable energy such as methane or ethane
Trained on curated data from Moorfields Eye Hospital, the neural network also shows clinicians how it reached its judgement